OPB-51602

DRUG4 trials

Sponsors

Otsuka Beijing Research Institute, Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc., National University Hospital, Singapore

Conditions

Acute Lymphoid LeukemiaAcute Myeloid LeukemiaAdvanced CancerChronic Myeloid LeukemiaMalignant Solid TumourMultiple MyelomaNasopharyngeal CarcinomaNon-Hodgkin Lymphoma

Phase 1

Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

CompletedNCT01184807

Otsuka Beijing Research InstituteMalignant Solid Tumour

Start: 2009-12-31End: 2013-06-30Updated: 2014-03-26

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

CompletedNCT01344876

Otsuka Pharmaceutical Co., Ltd.Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia +2

Start: 2011-04-30End: 2014-04-30Updated: 2015-06-08

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

CompletedNCT01423903

Otsuka Pharmaceutical Development & Commercialization, Inc.Advanced Cancer

Start: 2010-02-28End: 2013-04-30Updated: 2014-01-15

OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy

TerminatedNCT02058017

National University Hospital, SingaporeNasopharyngeal Carcinoma

Start: 2013-11-30End: 2015-05-31Updated: 2015-06-19

Related Papers

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

2015-01-21130 citations